Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S222000, C548S247000, C548S530000
Reexamination Certificate
active
07923470
ABSTRACT:
The present invention is concerned with novel sulfonamides of formula Iwherein R1, R2, Ar, Hetaryl, m and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
REFERENCES:
patent: WO 02/090355 (2002-11-01), None
patent: WO 2009/080533 (2009-07-01), None
Siegel, Annu. Rev. Psychol. vol. 55, pp. 125-148 (2004).
Delecea et al., Proc. Natl. Acad. Sci. USA vol. 95 pp. 322-327 (1998).
Sakurai et al., Cell vol. 92, pp. 573-585 (1998).
Sakurai, Regulatory Peptides vol. 126 pp. 3-10 (2005).
Peyron et al., J. Neurosci. vol. 18, pp. 9996-10015 (1998).
Nambu et al., Brain Res. vol. 827 pp. 243-260 (1999).
Chemelli et al., Cell, vol. 98 pp. 437-451 (1999).
Lin et al., Cell. vol. 98 pp. 365-376 (1999).
Nishino et al., Lancet vol. 355 pp. 39-40 (2000).
Peyron et al., Nature Medicine vol. 6 pp. 991-997 (2000).
Mignot et al., Sleep vol. 11 pp. 1012-1020 (1997).
Piper et al., Eur. J. Neuroscience vol. 12, pp. 726-730 (2000).
Sakamoto et al., Regul. Pept. vol. 118, pp. 183-191 (2004).
IDA et al., Biochem. Biophys. Res. Comm. vol. 270, pp. 318-323 (2000).
Kuru et al., Neuroreport vol. 11 pp. 1977-1980 (2000).
Winsky Sommerer et al., J. Neuroscience vol. 24 pp. 11439-11448 (2004).
Suzuki et al., Brain Research vol. 1044, pp. 116-121 (2005).
Digby et al., J. Endocrinol. vol. 191 pp. 129-136 (2006).
Cai, et al., Expert Opin. Ther. Patents vol. 16(5) pp. 631-646 (2006).
Bingham et al., Current Opinion in Drug Discovery & Development vol. 9(5) pp. 551-559 (2006).
Bourgin et al., J. Neurosci. vol. 20(20) pp. 7760-7765 (2000).
Smith, et al., Neurosci. Lett. vol. 341(3) pp. 256-258 (2003).
Malherbe et al., Mol. Pharmacol. vol. 64 pp. 823-832 (2003).
Yamazaki et al., Bioorganic & Medicinal Chemistry Letters vol. 17 pp. 4689-4693 (2007).
Chang et al., Neurosci. Research vol. 57, Issue 3, pp. 462-466 (2007).
Knust Henner
Nettekoven Matthias
Pinard Emmanuel
Roche Olivier
Rogers-Evans Mark
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Willis Douglas M
LandOfFree
Benzooxazoles as orexin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzooxazoles as orexin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzooxazoles as orexin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731267